[Cost-effectiveness analysis: a reader's guide].
This article is devoted to the critical appraisal of cost-effectiveness analysis. The example chosen concerns the choice of first line chemotherapy for a patient with stage IV non small cell bronchial carcinoma; a common problem in thoracic oncology. It compares three chemotherapy regimes: vinorelbine alone, cisplatin-vinorelbine and cisplatin-vindesine. The guide used allows evaluation of the validity of the methodology and, therefore, of the results obtained. The article studies the possible application of these results to the patient whose clinical history was presented as an introduction. The limitations of cost-effectiveness analyses are also considered.